Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
14 participants
INTERVENTIONAL
2017-04-15
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Macular Pigment and Glare Disability
NCT00909090
Carotenoid Supplementation and Normal Ocular Health
NCT02147171
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
NCT01048476
Carotenoid Supplementation and Retinal Health in Healthy Adults
NCT07314411
Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients With Age-related Macular Degeneration
NCT00879671
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
These include:
1. Medical History
2. Vital signs, Height and weight and BMI calculation
3. Visual Parameters
4. Blood draw for clinical chemistry and hematological safety
Intervention Period:
At baseline visual parameters and a serum sample for analysis of inflammatory markers will be taken. Supplements will be dispensed. Study visits will then be conducted every 3 months. At these visits, subjects will have visual parameters, adverse events, study diary, vitals, a questionnaire evaluating health/diet/exercise/alcohol, product distribution and compliance checked. A final serum/plasma sample will be taken at the final visit for re-assessment of safety parameters and inflammatory markers.
Compliance check:
The number of tablets dispensed at baseline and returned, as well as all intake information from a subject diary. Per protocol population is defined apriori as \>80%.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Will be identical looking to treatment
Placebo
Daily supplementation for 9 months
Lutein
10 mg of FloraGLO Lutein
Lutein
Daily Supplementation for 9 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Daily supplementation for 9 months
Lutein
Daily Supplementation for 9 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Corrected Visual Acuity of 20/20 to 20/25
* MPOD 0.05- 0.30 OD units
* Must be able to give written informed consent in English
* BMI \< or = 30 kg/m2
* Subject is willing to maintain a habitual diet and physical activity patterns throughout the study period
Exclusion Criteria
* Ocular pathologies
* History of active small bowel disease or resection
* Uncontrolled hypertension
* Diabetes mellitus
* Pancreatic disease
* Pregnancy (or planning to become pregnant) or lactation
* Diseases that interfere with fat absorption
* Medication or supplements that contain a significant level of carotenoids
* Medications that interfere with fat absorption
* Use of drugs suspected of interfering with metabolism of blood clotting
* Chronic alcohol intake
* Stroke, head injury with loss of consciousness or seizures
* Severe Amblyopia resulting in visual acuity worse than 0.4 MAR
* Subject is a heavy smoker (\> 1 pack/day)
* A regular consumer of lutein rich foods or lutein supplements
* A regular consumer of foods high in DHA intake or DHA supplements
* Subject has donated more than 300 mL of blood during the last three months prior to screening
40 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DSM Nutritional Products, Inc.
INDUSTRY
Kemin Foods LC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Manchester
Manchester, United Kindgom, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.